Instruction for use: Mixtard 30 HM

ATX Code A10AD01 Human insulin

Active substance Cetrorelix Insulin biphasic [human biosynthetic]

Pharmacological group

Insulins

Nosological classification (ICD-10)Z31.1 Artificial insemination

E10 Insulin-dependent diabetes mellitus

Decompensation of carbohydrate metabolism, Diabetes mellitus, Diabetes insulin sugar, Diabetes mellitus type 1, Diabetic ketoacidosis, Insulin-dependent diabetes, Insulin-dependent diabetes mellitus, Coma hyperosmolar non-ketoacidotic, Labile form of diabetes mellitus, Violation of carbohydrate metabolism, Type 1 diabetes mellitus, Type I diabetes mellitus, Insulin-dependent diabetes mellitus, Type 1 diabetes mellitus

E11 Non-insulin-dependent diabetes mellitus

Acetonuric diabetes, Decompensation of carbohydrate metabolism, Diabetes insulin-independent sugar, Diabetes sugar type 2, Type 2 Diabetes, Non-insulin-dependent diabetes, Non-insulin dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Insulin resistance, Insulin resistant diabetes mellitus, Coma lactobacillus diabetic, Violation of carbohydrate metabolism, Type 2 diabetes mellitus, Diabetes mellitus type II, Diabetes mellitus in adulthood, Diabetes mellitus in old age, Diabetes insulin-independent, Diabetes mellitus type 2, Sugar insulin-independent diabetes type II

Composition and form of release

1 ml of the suspension for injection contains biosynthetic human insulin 100 IU (soluble insulin 30% and isofan-insulin suspension 70%); In Penfill cartridges 3 ml for use with NovoPen 3 insulin syringe pen and NovoFine needles and in Penfill cartridges 1.5 ml for use in NovoPen or NovoPen II syringe pens; In blister packing 5 pcs. Or in 10 ml vials.

Characteristic

Suspension of monocomponent biosynthetic human insulin biphasic action.

pharmachologic effect

Pharmacological action - hypoglycemic.

Interacts with a specific receptor of the plasma membrane and penetrates into the cell, which activates the phosphorylation of cellular proteins, stimulates glycogen synthase, pyruvate dehydrogenase, hexokinase, inhibits fat lipase and lipoprotein lipase. In combination with a specific receptor facilitates the penetration of glucose into cells, enhances its assimilation by tissues and promotes conversion into glycogen. Increases the glycogen reserve in muscles, stimulates the synthesis of peptides.

Clinical Pharmacology

The effect develops 30 minutes after the SC administration, reaches a maximum after 2-8 hours and lasts for 24 hours.

Indications

Diabetes mellitus type I, type II diabetes mellitus (with resistance to sulfonylurea derivatives, intercurrent diseases, operations and post-operation period, during pregnancy).

Contraindications

Hypoglycemia, insulinoma.

Side effects

Allergic reactions; Hypoglycemia, refractive disorders (usually at the beginning of therapy).

Interaction

MAO inhibitors, non-selective beta-blockers, ACE inhibitors, salicylates, anabolic steroids, alcohol - increase, oral contraceptives, corticosteroids, thyroid hormones, thiazide diuretics, sympathomimetics - weaken the hypoglycemic effect.

Dosing and Administration

W / k (before use, the suspension should be gently mixed until uniformity is achieved). The dose and mode of administration are determined individually. When transferring a patient from a highly purified pig insulin to a human dose does not change, when transferred from beef or mixed - it is usually reduced by 10% (except when the total daily dose does not exceed 0.6 U / kg). A daily dose of 0.6 U / kg or more should be divided into 2-4 injections.

Overdose

Symptoms: development of hypoglycemia (cold sweat, palpitation, tremor, hunger, excitement, irritability, pallor, headache, drowsiness, movement uncertainty, speech and vision impairment, depression). Severe hypoglycemia can lead to temporary or permanent impairment of brain function, coma and death.

Treatment: sugar or glucose solution inside (if the patient is conscious), sc, v / m, or / in - glucagon or IV glucose.

Precautionary measures

The Penfill cartridge is designed exclusively for individual use. After injection for a minimum of 6 seconds, the needle should remain under the skin for complete dose administration. It should be borne in mind that the ability to drive after the transfer of patients to human insulin may temporarily decrease. Do not use the drug if the suspension does not become homogeneous with stirring.

special instructions

It is forbidden to use the drug if there are any damages on the surface of the Penfill cartridge.

Storage conditions

At a temperature of 2-8 ° C (do not freeze).

Keep out of the reach of children.

Shelf life

Suspension for subcutaneous administration of 100 IU / ml - 2.5 years.

Do not use after the expiry date printed on the package.